Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.63 |
| ▸ | AVPR1B | P47901 | 8/20 | 0.59 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004478 | 0.86 | ADRA1A (0.59) | ADRA1AKCNH2HRH3AVPR1BACHE | |
| SCHEMBL2003411 | 0.84 | ADRA1A (0.57) | ADRA1AKCNH2HRH3AVPR1BACHE | |
| SCHEMBL2002652 | 0.80 | HRH3 (0.59) | ADRA1AKCNH2HRH3AVPR1B | |
| SCHEMBL2007644 | 0.80 | KCNH2 (0.78) | ADRA1AKCNH2HRH3ACHE | |
| SCHEMBL2010232 | 0.79 | KCNH2 (0.57) | ADRA1AKCNH2HRH3AVPR1BACHE | |
| SCHEMBL2002247 | 0.79 | HRH3 (0.81) | ADRA1AKCNH2HRH3AVPR1B | |
| SCHEMBL2003640 | 0.77 | HRH3 (1.00) | ADRA1AKCNH2HRH3 | |
| SCHEMBL4473212 | 0.77 | HRH3 (0.80) | ADRA1AKCNH2HRH3 | |
| SCHEMBL2004603 | 0.76 | HRH3 (1.00) | ADRA1AKCNH2HRH3 | |
| SCHEMBL4468245 | 0.76 | HRH3 (0.82) | ADRA1AKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | ADRA1A 63/4885KCNH2 937/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.